Xconomy national.- Reforms to a US national security regulation are putting off foreign investors and driving down VC investment in the biotech space by as much as 20 percent, says BIO’s David Thomas.
2018年8月，国会通过了外国投资风险审查现代化法案（FIRRMA）作为2019财政国防授权法案的一部分。该法扩大了美国（CFIUS）委员会（CFIUS）的范围和监督，包括审查参与关键技术的公司的外国投资，全部以国家安全的名义。
裁决是否打算specifically curb investment from China, as many commentators at the time suggested根据生物技术创新组织（BIO），它对生物技术的风险投资（VC）投资产生了不利影响。
倡导集团工业研究副总裁David Thomas告诉我们，国会“扩大了规定，将生物技术作为需要受到国家安全目的所要求的这些核心领域之一，”另外的程序使外国投资者看起来其他市场。
US companies with foreign investment now have to go through an application and review process which can take months and involve substantial legal fees, Thomas told Xconomy journalist Mike Ward at the recent BIO-Europe® event in Hamburg, Germany. “It’s starting to slow things down, and we’ve seen a couple of investments not go through because one of the key components of a deal was this outside, foreign investment.”
BIO使用多个数据库来跟踪生物技术市场，而2019年官方数据将无法在明年年初提供，而初步数量显示在VC的投资将在前一年的投资下降约20％。
“We actually see it going up in Europe where we don’t have that policy,” Thomas continued, adding a further expansion in CFIUS’ remit is only going to push investors further away from US biotech companies.
“他们扩展了审查，将公司纳入患者遗传数据的公司。如果您的服务器上存储了遗传数据，则可能会在规则和规则下潜在[秋季]，因此，这几乎是在癌症和罕见的疾病中工作，在那里您需要某种类型的基因分型，“他补充道。
This latest expansion of CFIUS is only in a pilot stage, and Thomas said continued advocacy could help reverse the VC spending trend. “The government is trying to find out where to draw the line and BIO’s role is to have conversations with the Treasury to identify how broad this is and maybe where that scope could be narrowed.”
药物定价提案
Thomas also spoke about the impact of proposed pricing controls in the US, specifically plans to reference drug prices in the US to those in Europe and Japan. The result, he said, is that the biotech index is down 13 percent over the past four and a half years, when conversations about drug pricing really began. “Things have gone up and down but really never recovered back to those 2015-2016 highs,” Thomas added.
The most extreme plan is the民主党人的HR3账单，由扬声器南希·佩洛西提出。The国会预算办公室（CBO）于十月表示that the bill could lead to a reduction in drug manufacturers’ revenues of $500 billion to $1 trillion over the next 10 years and “would lead to a reduction of approximately eight to 15 new drugs coming to market.” The FDA approves about 30 new drugs yearly, suggesting it would otherwise OK about 300 in that time, the CBO noted.
双O’s own analysis, done in conjunction with the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Council of State Bioscience Associations (CSBA)那has placed the figure at around 56 fewer new medicines for patients over the next 10 years, but Thomas told us the actual figure could be even higher in the longer-term.
“现在刚刚开始创新的一些公司的公司将需要10到20年，”他说。“将较少的资金进入这些公司，因此如果您查看较长的时间框架，它可能会成为另一个零点。它会造成毁灭性的创新。“
大多数药物公司将研发预算固定为其收入的百分比 -roughly 15 to 20 percent他补充说， - 控制药价格意味着更少的研发，更少的创新，较少的资金，而且合作活动的资金较少。亚博游戏城“这里可能存在较少的有益交易条款或整体的较少交易，这影响了这一事件的每个人。”
Gain more insights into venture capital investment in biotech by attending Biotech Showcase™, the investor conference that drives the future of drug development。
这篇文章最初发表在Xconomy。https://xconomy.com/national/2019/11/29/biotech-vc-down-20-in-us-as-policies-drive-away-foreign-investors-bio/
